BIOMAT Database Logo BIOMAT Database Logo

Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases. 2007

Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
INSERM, U 716, Equipe AVENIR, Institut de Génétique Moléculaire, Paris 75010, France.

The proprotein convertases (PCs) are responsible for the endoproteolytic processing of various protein precursors (e.g., growth factors, receptors, adhesion molecules, and matrix metalloproteinases) implicated in several diseases such as obesity, diabetes, atherosclerosis, cancer, and Alzheimer disease. The potential clinical and pharmacological role of the PCs has fostered the development of various PC-inhibitors. In this review we summarized the recent findings on PCs inhibitors, their mode of actions and potential use in the therapy of various diseases.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D043484 Proprotein Convertases Proteolytic enzymes that are involved in the conversion of protein precursors such as peptide prohormones into PEPTIDE HORMONES. Some are ENDOPEPTIDASES, some are EXOPEPTIDASES. Pro-Opiomelanocortin Converting Enzyme,Prohormone Convertases,Proprotein Convertase,POMC Convertase,POMC Enzyme,POMC-Converting Enzyme,Pro-Opiocortin Converting Enzyme,Pro-Opiocortin Converting Protease,Prohormone Convertase,Proopiomelanocortin Convertase,Proprotein Convertase, Subtilisin-Kexin Family,Proprotein Convertases, Subtilisin-Kexin Family,Subtilisin-Like Proprotein Convertases,Convertase, POMC,Convertase, Prohormone,Convertase, Proopiomelanocortin,Convertase, Proprotein,Convertases, Prohormone,Convertases, Proprotein,Convertases, Subtilisin-Like Proprotein,Converting Enzyme, Pro-Opiocortin,Converting Enzyme, Pro-Opiomelanocortin,Converting Protease, Pro-Opiocortin,POMC Converting Enzyme,Pro Opiocortin Converting Enzyme,Pro Opiocortin Converting Protease,Pro Opiomelanocortin Converting Enzyme,Proprotein Convertase, Subtilisin Kexin Family,Proprotein Convertases, Subtilisin Kexin Family,Proprotein Convertases, Subtilisin-Like,Subtilisin Like Proprotein Convertases

Related Publications

Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
Inhibitors of proprotein convertases.
November 2005, Journal of molecular medicine (Berlin, Germany),
Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
The potential anti-tumorigenic and anti-metastatic side of the proprotein convertases inhibitors.
January 2009, Recent patents on anti-cancer drug discovery,
Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
The biology and therapeutic targeting of the proprotein convertases.
May 2012, Nature reviews. Drug discovery,
Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
Therapeutic and Diagnostic Agents based on Bioactive Endogenous and Exogenous Coordination Compounds.
January 2024, Current medicinal chemistry,
Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
The proprotein convertases are potential targets in the treatment of dyslipidemia.
July 2007, Journal of molecular medicine (Berlin, Germany),
Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
Proprotein Convertases and the Complement System.
January 2022, Frontiers in immunology,
Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
Subtilisin-like proprotein convertases, PACE4 and PC8, as well as furin, are endogenous proalbumin convertases in HepG2 cells.
March 1999, Journal of biochemistry,
Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
Proprotein convertases in health and disease.
December 2011, The New England journal of medicine,
Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
Development of Pin1 Inhibitors and their Potential as Therapeutic Agents.
January 2020, Current medicinal chemistry,
Yannick Bontemps, and Nathalie Scamuffa, and Fabien Calvo, and Abdel-Majid Khatib
The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
January 2017, Pharmacological reviews,
Copied contents to your clipboard!